FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
14 letters match. Newest first.
-
DrugsBaxter International Inc.
Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.
High risk -
AnimalSciarra Aeromed, Inc.
Sciarra Aeromed's purportedly sterile veterinary drug was contaminated and made under insanitary conditions, FDA says.
High risk -
AnimalNeogen Corporation
FDA found Neogen's HYCOAT animal drug contaminated and made under insanitary conditions after horse deaths.
High risk -
DrugsFresenius Kabi USA LLC
FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.
High risk -
DrugsEmpower Clinic Services, LLC dba Empower Pharmacy
FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.
High risk -
DrugsBausch & Lomb Inc.
FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.
High risk -
DrugsEugia Pharma Specialities Limited
FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.
High risk -
DrugsK.C. Pharmaceuticals, Inc.
FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.
High risk -
DrugsFareva Amboise
FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.
High risk -
DrugsWizcure Pharmaa Private Limited
FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
High risk -
DrugsJubilant HollisterStier General Partnership
FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.
High risk -
DrugsPar Health USA, LLC & Endo USA, Inc.
FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.
High risk -
DrugsNew Life Pharma LLC
New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.
High risk -
DrugsThrive Health and Wellness, LLC dba Thrive Health Solutions
FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.
High risk